A significant proportion of patients with stage I to III NSCLC or SCLC will have locoregional or distant metastases following curative-intent therapy. Studies have reported local recurrence rates of 22% […] Read more
For patients with metastatic lung cancer, frequent scans are a stark reality of living with cancer. Although most scans happen every 3 months, some clinical trials require scans more often […] Read more
Identification of driver oncogenes in NSCLC is leading the method for accurate patient selection and proper targeting of actionable alterations. Several molecular events have been described, and different biomarkers are […] Read more
Lung cancer screening saves lives. This once controversial statement has now been validated in recent large, randomized trials of low-dose computed tomographic (LDCT) lung cancer screening (LCS) including the National […] Read more
Lung cancer remains the leading cause of cancer-related deaths.1 Advances in early detection of lung cancer following the implementation of screening programs and the availability of newer therapies have increased […] Read more
Ben Levy, MD When it comes to the use of metformin as a treatment for lung cancer, the jury is still out on its potential. “Metformin’s utility as an anticancer […] Read more
Therapies for NSCLC have evolved over the past 2 decades to account for the specific biology of the tumor and have improved outcomes for a multitude of patients. Discovery of […] Read more
When patients with advanced metastatic NSCLC initially make their way into our medical oncology clinic, one of the first things we check for is the molecular pathology testing report, in […] Read more
Dr. Negrao is an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center. Dr. Negrao has a diverse experience in […] Read more
Christine Lovly, MD, PhD Christine Lovly, MD, PhD, and Helena Yu, MD, have been awarded the 2021 EGFR Resisters/LUNGevity Lung Cancer Research Award. Each award totals $200,000 for a two-year […] Read more